⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30783153 | 1.00 | — | — | |
| SCHEMBL413011 | 0.77 | — | — | |
| SCHEMBL29486472 | 0.77 | — | — | |
| SCHEMBL28628599 | 0.75 | — | — | |
| SCHEMBL3678352 | 0.75 | — | — | |
| SCHEMBL30398249 | 0.75 | — | — | |
| SCHEMBL29374917 | 0.75 | — | — | |
| SCHEMBL7887262 | 0.75 | — | — | |
| SCHEMBL1056076 | 0.75 | — | — | |
| SCHEMBL29479544 | 0.75 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3901151-B1 | HALOGENATED-HETEROARYL AND OTHER HETEROCYCLIC KINASE INHIBITORS, AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2026-04-01 | — | — | EP | disclosed |
| US-12590102-B2 | Compound and organic light emitting device comprising the same | LG CHEM, LTD. (KR) | 2026-03-31 | — | — | US | disclosed |
| EP-3643713-B1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-07-30 | — | — | EP | disclosed |
| US-20250101015-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-27 | — | — | US | disclosed |
| US-20250084076-A1 | HETEROCYCLIC KINASE INHIBITORS AND USES THEREOF | IOMX THERAPEUTICS AG (DE) | 2025-03-13 | — | — | US | disclosed |
| US-12172993-B2 | Heterocyclic kinase inhibitors and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-12-24 | — | — | US | disclosed |
| US-12139480-B2 | 5-thiazolecarboxamide kinase inhibitor and uses thereof | IOMX THERAPEUTICS AG (DE) | 2024-11-12 | — | — | US | disclosed |
| CN-115190879-B | Novel compound and organic light emitting device comprising the same | 株式会社LG化学 | 2024-04-30 | — | — | CN | disclosed |
| CN-114845997-B | Aromatic compound and application thereof in preparation of antitumor drugs | 上海喆邺生物科技有限公司 | 2024-03-29 | — | — | CN | disclosed |
| US-20240101573-A1 | MACROCYCLIC K-RAS G12C INHIBITOR, PREPARATION METHOD THEREFOR AND USE THEREOF | ABBISKO THERAPEUTICS CO., LTD. (CN) | 2024-03-28 | — | — | US | disclosed |
| EP-1257276-A4 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL MYERS SQUIBB CO (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040023982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2004-02-05 | — | — | US | disclosed |
| US-6632819-B1 | HIV and AIDS | BRISTOL-MYERS SQUIBB COMPANY | 2003-10-14 | — | — | US | disclosed |
| US-20030181463-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2003-09-25 | — | — | US | disclosed |
| CN-1404392-A | Antiviral azaindole derivatives | BRISTOL MYERS SQUIBB CO (US) | 2003-03-19 | — | — | CN | disclosed |
| EP-1257276-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-11-20 | — | — | EP | disclosed |
| US-6476034-B2 | AIDS THERAPY | BRISTOL-MYERS SQUIBB COMPANY | 2002-11-05 | — | — | US | disclosed |
| US-20020119982-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-08-29 | — | — | US | disclosed |
| US-20020061892-A1 | Antiviral azaindole derivatives | VIIV HEALTHCARE UK (NO. 5) LIMITED (GB) | 2002-05-23 | — | — | US | disclosed |
| WO-2001062255-A1 | ANTIVIRAL AZAINDOLE DERIVATIVES | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-08-30 | — | — | WO | disclosed |